Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat

Muneera A P; Grinish Pravinbhai Tamakuwala; Jignesh Gengadiya; Parul Vadgama

doi:10.5455/njppp.2023.13.06314202322062023

2024, Vol: 14, Issue: 5

14 / 5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
29 / 06 / 2023

Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1744-1750

doi: 10.5455/njppp.2023.13.06314202322062023

Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat

Muneera A P, Grinish Pravinbhai Tamakuwala, Jignesh Gengadiya, Parul Vadgama.

Abstract
Background: India remains one of the six countries with an enormous multidrug-resistant tuberculosis (MDR TB) burden. Shorter MDR regimen is more economical/cheaper, shorter and having an improved adherence for Rifampicin resistant (RR)-TB. There were not many studies on this shorter MDR regimen (containing high-dose moxifloxacin) in India, we had carried out this study to find out outcomes and adverse drug reactions (ADRs) of this Shorter MDR regimen.

Aims and Objectives: To study the clinical profile, interim and final outcome, and ADRs in RR-TB patients taking shorter MDR regimens.

Materials and Methods: Prospective observational longitudinal study which was carried out in the Department of Respiratory Medicine Department, New Civil Hospital, Surat from January 2019 to June 2020. All patients who were diagnosed as RR-TB by cartridge-based nucleic acid amplification were enrolled in the study. Eligible Patients (n = 60) were started on shorter MDR regimen and were followed up.

Results: Out of these 60 patients 35 (58.3%) were male and 25 (41.6%) were female. The age group mainly included was between 20 and 40 years. Out of 60 patients, 55 (91.6%) had pulmonary and 5 (8.3%) had extrapulmonary TB. Interim Outcome in the form of culture conversion at the end of 4th, 5th, and 6th month was seen in 21 (45.65%), 37 (80.43%), and 45 (97.83%), respectively. The final outcome among 60 patients were 33 (55%) cured, 12 (20%) treatment completed, 6 (10%) lost to follow-up, 5 (8.33%) regimen changed, 3 (5%) died, and failure in 1 (1.66%). These results were matching with most of the other studies.

Conclusion: This study showed successful outcome (cured and treatment completed) in 45 patients (75%) and adverse outcome (died, lost to follow-up, and failure) in 10 patients (16.67%). A shorter MDR regimen is shorter, cheaper, effective in most of the RR-TB patients and is well tolerated with mild side effects.

Key words: Multidrug Resistant; Rifampicin Resistant; Adverse Drug Reaction; Cartridge Based Nucleic Acid Amplification; Extra Pulmonary Tuberculosis

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Muneera A P Articles by Grinish Pravinbhai Tamakuwala Articles by Jignesh Gengadiya Articles by Parul Vadgama
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

P MA, Tamakuwala GP, Gengadiya J, Vadgama P. Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Web Style

P MA, Tamakuwala GP, Gengadiya J, Vadgama P. Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. https://www.njppp.com/?mno=156424 [Access: March 14, 2024]. doi:10.5455/njppp.2023.13.06314202322062023

AMA (American Medical Association) Style

P MA, Tamakuwala GP, Gengadiya J, Vadgama P. Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Vancouver/ICMJE Style

P MA, Tamakuwala GP, Gengadiya J, Vadgama P. Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. Natl J Physiol Pharm Pharmacol. (2023), [cited March 14, 2024]; 13(2023, Vol: 13, Issue: 8): 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Harvard Style

P, M. A., Tamakuwala, . G. P., Gengadiya, . J. & Vadgama, . P. (2023) Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. Natl J Physiol Pharm Pharmacol, 13 (2023, Vol: 13, Issue: 8), 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Turabian Style

P, Muneera A, Grinish Pravinbhai Tamakuwala, Jignesh Gengadiya, and Parul Vadgama. 2023. Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Chicago Style

P, Muneera A, Grinish Pravinbhai Tamakuwala, Jignesh Gengadiya, and Parul Vadgama. "Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

MLA (The Modern Language Association) Style

P, Muneera A, Grinish Pravinbhai Tamakuwala, Jignesh Gengadiya, and Parul Vadgama. "Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat." National Journal of Physiology, Pharmacy and Pharmacology 13.2023, Vol: 13, Issue: 8 (2023), 1744-1750. Print. doi:10.5455/njppp.2023.13.06314202322062023

APA (American Psychological Association) Style

P, M. A., Tamakuwala, . G. P., Gengadiya, . J. & Vadgama, . P. (2023) Clinical profile and outcome in patients with rifampicin-resistant tuberculosis taking shorter multidrug-resistant tuberculosis treatment regimen at a tertiary care hospital in South Gujarat. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1744-1750. doi:10.5455/njppp.2023.13.06314202322062023

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272